News
-
-
-
-
-
-
-
-
PRESS RELEASE
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting -
-
PRESS RELEASE
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
New to The Street's long-form corporate storytelling programs featuring PetVivo and Acurx Pharmaceuticals exceed 200,000 views, establishing as a leading platform for investor-focused content